| Name | Title | Contact Details |
|---|
At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible. PolyNovo develops innovative medical devices utilizing the patented bioabsorbable polymer technology Novosorb®. NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways. NovoSorb BTM (Biodegradable Temporizing Matrix) is the first product commercialized by PolyNovo. In 2015, following the FDA 510(K) clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns. We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.
Bruce Leeb and Company is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Wound Pros, LLC is a physician-owned Medicare Part B supplier of the industry’s most advanced wound care dressings. As a bonus, Wound Pros offers excellent clinical expertise which gives our patients the best opportunity to heal efficiently. Our vision is to change the way the world treats and manages non-healing wounds. Chronic non-healing wounds can compromise the quality of life for those living in long-term care facilities. The longer a wound remains open or unhealed, the greater the chance of unwanted complications such as infection, hospitalisation, and even amputation. At The Wound Pros, we are dedicated to meeting this challenge head-on with our "Hi-Tech Hi-Touch Approach” to wound care management. Our vision is to change the way the world treats and manages chronic non-healing wounds with better data, better decision making and better documentation.
NAVEOS® is the proven leader in maximizing the value of governmental program reimbursements for healthcare providers. Since 2005, our superior approach to data analytics has enabled healthcare providers to realize almost one billion dollars in additional DSH/340B reimbursement payments. NAVEOS® has developed a fully integrated DSH/340B software solution with a national eligibility verification network for both Medicare and Medicaid data. This system, which is the most robust in the industry, uses sophisticated algorithms to match eligibility data with patient data, applies the most up to date Federal and State regulatory parameters, then builds comprehensive deliverables for supporting DSH/340B filings. By leveraging our state-of-the-art technology and unsurpassed domain expertise, we generate best-in-class deliverables that yield impressive value and achieve a stellar (99.7%) audit acceptance rate.
Hallman Group is a Kalamazoo, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.